Galapagos gets full rights to molecule from GSK; Norway emerges as biotech force;

 @FierceBiotech: PwC sees big 2Q jump in biotech venture investments. Article | Follow @FierceBiotech

 @JohnCFierce: Reuters reduced to quoting Genzyme staffer fearing layoffs in a post-merger world. What, no new insider leaks? Article | Follow @JohnCFierce

> Galapagos has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the company's arthritis alliance with GSK. Galapagos is initiating a Phase I clinical trial with this selective JAK inhibitor. Galapagos release

> Norway, which built its wealth on salmon and oil, is emerging as a force in biotechnology as companies around Oslo discover new ways to fight cancer. Article

> Novavax (Nasdaq: NVAX) announced today the appointment of Richard Douglas to its board of directors. Dr. Douglas is currently senior VP, corporate development at Genzyme. Novavax release

> Takeda Pharmaceutical and partner Affymax say they intend to file their investigational anaemia drug Hematide during the first half of 2011. Story

> Micromet (Nasdaq:MITI) has announced its financial results for the second quarter and six months that ended June 30, 2010. For the three months ended June 30, 2010, Micromet recognized total revenues of $6.5 million, compared to $4.9 million for the same period in 2009. Micromet's release

> Poland's treasury ministry and the pharmaceuticals group Polski Holding Farmaceutyczny have decided to sell off the latter's subsidiary, Polfa Tarchomin. Story

> Scientists announced the discovery of genetic changes that affect the spread of Influenza virus from one host to another. In a report in the current edition of Public Library of Science (PLoS) Pathogens, an international team of scientists--including members of the Seattle Structural Genomics Center for Infectious Disease (SSGCID)--sheds new light on the Influenza virus, showing that the recent pandemic-causing H1N1 flu virus used a new biochemical trick to spread efficiently in humans. SSGCID release

And Finally... Tissue from the hearts of mice morphed into muscle cells with the ability to beat and form electrical connections, in an experiment that may lead to new therapy for more than 5 million Americans with heart failure. Article

Suggested Articles

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

LianBio aims to bring much-needed new drugs to China and serve as a partner for U.S. biotechs looking to expand into Asia.